CSIMarket
 
Enovis Corp  (NYSE: ENOV)
 
Price: $18.5600 $-0.84 -4.330%
Day's High: $19.31999969482422 Week Perf: -24.52 %
Day's Low: $ 18.52 30 Day Perf: -29.46 %
Volume (M): 1,886,159 52 Wk High: $ 34.28
Volume (M$): $ 0 52 Wk Avg: $26.05
Open: $19.01 52 Wk Low: $18.52



 Market Capitalization (Millions $) 1,069
 Shares Outstanding (Millions) 58
 Employees 7,802
 Revenues (TTM) (Millions $) 2,295
 Net Income (TTM) (Millions $) -1,101
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 163

Business Description


Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth eXcellence business system (eEGXe), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.


   Company Address: 2711 Centerville Road, Wilmington, 19808 DE
   Company Phone Number: 252-9160   Stock Exchange / Ticker: NYSE ENOV


Customers recorded net loss Customers recorded net loss



• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EW   -0.34%    
GMED   -5.64%    
MDT        3.22% 
SYK   -8.33%    
TFX   -0.94%    
ZBH   -2.81%    
• View Complete Report
   



Announcement

Navigating Change Enovis Corporations Leadership Transition Amid Market Challenges

Published Wed, Feb 26 2025 11:15 AM UTC

By In a significant leadership transition, Enovis Corporation, a prominent player in medical technology, announced on February 26, 2025, that CEO Matt Trerotola will retire once a successor is appointed. This decision comes as the company grapples with a challenging market environment, where its stock has underperformed against broader market trends.Trerotola has informed t...

Announcement

Innovations in Surgical Technologies Enovis Strengthens Leadership and Expands Product Portfolio

Published Mon, Sep 9 2024 7:50 PM UTC

In the dynamic landscape of medical technology, innovation is the bedrock on which successful companies are built. Enovis, a prominent player in the sector and listed on the New York Stock Exchange under the ticker ENOV, continues to exemplify this principle through strategic leadership appointments and groundbreaking product advancements. Recently, the company announced the...

Announcement

Enovis Propels Foot and Ankle Surgery into the Future with Innovative Solutions at AOFAS Annual Meeting,

Published Thu, Sep 5 2024 12:01 PM UTC

Enovis Unveils Groundbreaking Foot and Ankle Solutions at AOFAS Annual Meeting Stepping boldly into the future of orthopedic surgery, Enovis Foot & Ankle is set to revolutionize the field with its latest offerings. At the upcoming AOFAS Annual Meeting, the company will introduce the highly anticipated Tarsoplasty solution and present live demonstrations of its Better Step pa...

Announcement

for the Enovis Transforms Knee Revision Surgery with EMPOWR Cones, Reports Staggering 22.53% Revenue Growth Amid...

Published Tue, Aug 20 2024 12:00 PM UTC

Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR Cones to EMPOWR Revision Knee, Witnesses Revenue SurgeIn a revolutionary stride towards optimizing revision knee surgery, Enovis Corp announced the successful completion of the first surgeries using the newly-integrated EMPOWR Cones with the EMPOWR Revision Knee system. This advancement, executed...

Product Service News

Enovis Enhances Orthopedic Care with STAR Ankle and DonJoy ROAM Innovations,

Published Mon, Aug 19 2024 12:00 PM UTC

Leading the Charge in Orthopedic Innovation: Enovis Unveils Game-Changing Ankle and Knee TechnologiesIn an era where advancements in medical technology are surging, Enovis, a prominent player in the orthopedic industry, has made significant strides with the introduction of two groundbreaking products: the STAR Ankle system and the DonJoy ROAM OA Knee Brace. Both innovations...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.47
Price to Sales (Expected) -
Price to Book 0.72
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.02
Working Capital Ratio 1.65
Leverage Ratio (MRQ) 1.63
Total Debt to Equity 0.89
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -19.28 $
Revenues (TTM) 39.84 $
Cash Flow (TTM) -
Cash 0.22 $
Book Value 25.68 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 294,147
Net Income per Employee (TTM) -141,099
Receivable Turnover Ratio (TTM) 5.21
Inventory Turnover Ratio (TTM) 1.49
Asset Turnover Ratio (TTM) 0.58

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 2.99 %
Net Margin (MRQ) -0.18 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Enovis's Segments
Prevention and Recovery    96.14 % of total Revenue
Reconstructive    104.96 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.